RxDoctor Payments Data

Todd Severin, MD

Ophthalmology · San Ramon, CANPI 1144225343

Payments from drug & device makers

$87,513in general payments, 2019–2025

Across 306 payments — averaging $285.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$59K
  • Aerie Pharmaceuticals, Inc.$11K
  • Alcon$7K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
  • AbbVie$2K
  • Johnson & Johnson Surgical Vision, Inc.$1K
  • plus $3K from 21 others

What the payments were for

  • Consulting fees$59,83268%
  • Speaking & faculty fees$20,26623%
  • Travel & lodging$780%
  • Food & beverage$7,1958%
  • Education$980%
  • Gifts$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,513 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$422,238
Medicare patients
816
Services billed
4,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost607$301,486
RocklatanNetarsudil Mesylat/Latanoprost289$160,667
CombiganBrimonidine Tartrate/Timolol85$43,892
Alphagan PBrimonidine Tartrate72$35,445
VyzultaLatanoprostene Bunod55$33,749
CequaCyclosporine22$29,355
RestasisCyclosporine17$26,339
SimbrinzaBrinzolamide/Brimonidine Tart62$17,352
Brimonidine Tartrate180$17,179
Cyclosporine19$16,890
Brinzolamide96$15,589
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol85$14,926
MieboPerfluorohexyloctane/Pf13$12,710
Latanoprost985$12,627
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat575$11,772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P, Restasis$2,088$407,162781 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$10,546$171,617304 claims
Bausch & Lomb Americas Inc.Vyzulta, Miebo$331$46,45968 claims
Sun Pharmaceutical Industries Inc.Cequa$396$29,35522 claims
AlconSimbrinza$6,874$17,35262 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm$5,237$11,02934 claims
Thea Pharma Inc.Iyuzeh$138$8,12516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Ramon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →